Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes

References

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–447
   PubMed Web of Science ®Google Scholar
• Ellegaard J, Nielsen J L. Angiogenesis in malignant blood diseases. Ugeskr Laeger 1999; 161: 4012
   PubMedGoogle Scholar
• Mangi M H, Newland A C. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000; 111: 43–51
   PubMed Web of Science ®Google Scholar
• Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211–220
   PubMed Web of Science ®Google Scholar
• Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi B Z. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5: 89–97
   PubMedGoogle Scholar
• Olofsson B, Pajusola K, Kaipainen A, von E G, Joukov V, Saksela O, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci 1996; 93: 2576–2581
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I K, Alitalo, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290–298
   PubMed Web of Science ®Google Scholar
• Achen M G, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks A F, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci 1998; 95: 548–553
   PubMed Web of Science ®Google Scholar
• Hansen S, Grabau D A, Rose C, Bak M, Sorensen F B. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 1998; 78: 1563–1573
   PubMed Web of Science ®Google Scholar
• Fox S B, Leek R D, Weekes M P, Whitehouse R M, Gatter K C, Harris A L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995; 177: 275–283
   PubMed Web of Science ®Google Scholar
• Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883–893
   PubMed Web of Science ®Google Scholar
• Vermeulen P B, Gasparini G, Fox S B, Toi M, Martin L, McCulloch P, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474–2484
   PubMed Web of Science ®Google Scholar
• Macchiarini P, Fontanini G, Hardin M J, Squartini F, Angeletti C A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145–146
   PubMed Web of Science ®Google Scholar
• Weidner N, Carroll P R, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401–409
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung Y S, Takatsuka S, Ogawa Y, Onoda N, Sawada T, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995; 72: 319–323
   PubMed Web of Science ®Google Scholar
• Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995; 36: 193–204
   PubMed Web of Science ®Google Scholar
• Hansen S, Sorensen F B, Vach W, Grabau D A, Bak M, Rose C. Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology 2004; 44: 428–436
   PubMed Web of Science ®Google Scholar
• Hansen S, Grabau D A, Sorensen F B, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000; 6: 139–146
   PubMed Web of Science ®Google Scholar
• Hansen S, Grabau D A, Sorensen F B, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer 2000; 82: 339–347
   PubMed Web of Science ®Google Scholar
• Hussong J W, Rodgers G M, Shami P J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79: 451–455
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508
   PubMed Web of Science ®Google Scholar
• Pruneri G, Ponzoni M, Ferreri A J, Decarli N, Tresoldi M, Raggi F, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002; 118: 817–820
   PubMed Web of Science ®Google Scholar
• Andersen N F, Standal T, Nielsen J L, Heickendorff L, Borset M, Sorensen F B, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210–217
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 1995; 20: 27–38
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Fanelli M, Costantino F, Nico B, Di S R, et al. Expression of tenascin is related to histologic malignancy and angiogenesis in b-cell non-Hodgkin's lymphomas. Leuk Lymphoma 1996; 22: 473–481
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56: 45–53
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79: 965–970
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L, Dammacco F. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer 2000; 85: 171–175
   PubMed Web of Science ®Google Scholar
• Crivellato E, Nico B, Vacca A, Ribatti D. B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. Haematologica 2003; 88: 671–678
   PubMed Web of Science ®Google Scholar
• Arias V, Soares F A. Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 2000; 40: 157–166
   PubMed Web of Science ®Google Scholar
• Fukushima N, Satoh T, Sano M, Tokunaga O. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2001; 42: 709–720
   PubMed Web of Science ®Google Scholar
• Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 2089–2093
   PubMed Web of Science ®Google Scholar
• Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol 2000; 17: 314–318
   PubMed Web of Science ®Google Scholar
• Koster A, van Krieken J H, Mackenzie M A, Schraders M, Borm G F, van der Laak J A, et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005; 11: 154–161
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334–3339
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712–3718
   PubMed Web of Science ®Google Scholar
• Giles F J, Vose J M, Do K A, Johnson M M, Manshouri T, Bociek G, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004; 28: 595–604
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 68: 91–100
   PubMed Web of Science ®Google Scholar
• Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci P F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504–509
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167–3172
   PubMed Web of Science ®Google Scholar
• Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003; 97: 2767–2775
   PubMed Web of Science ®Google Scholar
• Aref S, Mabed M, Zalata K, Sakrana M, El A H. The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome. Leuk Lymphoma 2004; 45: 499–506
   PubMed Web of Science ®Google Scholar
• Ho C L, Sheu L F, Li C Y. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2002; 10: 316–321
   PubMedGoogle Scholar
• Ho C L, Sheu L F, Li C Y. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 2003; 7: 1–8
   PubMedGoogle Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. WHO Classification of Tumours, Pathology and Genetics of Tumours of Haemopoetic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Yuen A R, Kamel O W, Halpern J, Horning S J. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13: 1726–1733
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587–1594
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Vacca A, Marzullo A, Calvi N, Roncali L, et al. Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas?. Br J Cancer 1998; 77: 1900–1906
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, Piccaluga P P, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24: 2472–2479
   PubMed Web of Science ®Google Scholar
• Perea G, Altes A, Montoto S, Lopez-Guillermo A, Domingo-Domenech E, Fernandez-Sevilla A, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005; 16: 1508–1513
   PubMed Web of Science ®Google Scholar
• Ansell S M, Habermann T M, Kurtin P J, Witzig T E, Chen M G, Li C Y, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296–2301
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt W P, Muller-Hermelink H K, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129: 366–372
   PubMed Web of Science ®Google Scholar
• De R H, Van M E, Van C B, Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol 2004; 19: 935–950
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti A K, Kargas S, Koch M. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002; 22: 2899–2901
   PubMed Web of Science ®Google Scholar
• Yancopoulos G D, Davis S, Gale N W, Rudge J S, Wiegand S J, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–248
   PubMed Web of Science ®Google Scholar
• Jiang W G, Martin T A, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005; 53: 35–69
   PubMed Web of Science ®Google Scholar
• Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82: 673–700
   PubMed Web of Science ®Google Scholar
• Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000; 96: 3139–3146
   PubMed Web of Science ®Google Scholar